Related Experiment Videos
[Antihypertensive treatment with cardiotensin. A clinical study (author's transl)]
MMW, Munchener Medizinische Wochenschrift
|February 15, 1980
Insights
This study found that Cardiotensin effectively treats hypertension stages I and II in adults aged 30-50. The combination product demonstrated efficacy in primary and secondary hypertension with minimal side effects at lower doses.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Hypertension management is a significant public health concern.
- Combination therapies are increasingly explored for improved patient outcomes.
Purpose:
- To evaluate the efficacy and safety of Cardiotensin, a combination product, for treating hypertension.
- To determine appropriate dosage and patient populations for Cardiotensin therapy.
Summary:
- Clinical study results indicate Cardiotensin is effective for hypertension stages I and II.
- The medication shows promise in treating both primary and secondary hypertension.
- Optimal use observed in patients aged 30-50 years, utilizing lower doses with no severe adverse effects.
Impact:
- Cardiotensin offers a potential new treatment option for a broad range of hypertensive patients.
- Low-dose application suggests a favorable safety profile, potentially improving patient adherence.
- Findings support the use of combination products in managing essential and secondary hypertension.
Abstract:
After an explanation of the treatment of hypertension the results of a clinical study using the combination product Cardiotensin are presented. The results in regard to the components of this product show, that the medicament can be used in hypertension show, that the medicament can be used in hypertension stages I and II and in primary and secondary hypertension especially inthe age of 30--50 years at lower doses without severe side effects.